After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026

Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.